CYTEK BIOSCIENCES INC (CTKB) Stock Analyst Ratings
USA - NASDAQ:CTKB - US23285D1090 - Common Stock
4.26 USD
+0.1 (+2.4%)
4.26 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 78% to CTKB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.23. This target is 22.71% above the current price.
CTKB was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CTKB.
In the previous month the buy percentage consensus was at a similar level.
CTKB was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-28 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-12 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-03-19 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-08-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-03-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-02-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-12-14 | Stephens & Co. | Initiate | Overweight |
| 2023-11-09 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-10-24 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-10-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-07-19 | Raymond James | Initiate | Market Perform |
| 2023-05-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-05-10 | Goldman Sachs | Maintains | Buy |
| 2023-03-07 | Piper Sandler | Maintains | Overweight |
| 2023-03-02 | Goldman Sachs | Maintains | Buy |
| 2023-03-02 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-08-18 | Piper Sandler | Maintains | Overweight |
| 2022-08-12 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-08-11 | Goldman Sachs | Maintains | Buy |
| 2022-07-14 | Goldman Sachs | Maintains | Buy |
| 2022-05-16 | Piper Sandler | Maintains | Overweight |
| 2022-05-13 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-05-12 | Goldman Sachs | Maintains | Buy |
| 2022-04-13 | Goldman Sachs | Maintains | Buy |
| 2022-02-15 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-08-17 | Cowen & Co. | Initiate | Outperform |
| 2021-08-17 | Goldman Sachs | Initiate | Buy |
CYTEK BIOSCIENCES INC / CTKB FAQ
What is the average price target for CYTEK BIOSCIENCES INC (CTKB) stock?
11 analysts have analysed CTKB and the average price target is 5.23 USD. This implies a price increase of 22.71% is expected in the next year compared to the current price of 4.26.
What is the consensus rating for CYTEK BIOSCIENCES INC (CTKB) stock?
The consensus rating for CYTEK BIOSCIENCES INC (CTKB) is 78.1818 / 100 . This indicates that analysts generally have a positive outlook on the stock.